<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03831828</url>
  </required_header>
  <id_info>
    <org_study_id>HebeiMUFH-ESCC</org_study_id>
    <nct_id>NCT03831828</nct_id>
  </id_info>
  <brief_title>Correlation of Gene Status and Clinical Outcomes in ESCC</brief_title>
  <acronym>ESCC</acronym>
  <official_title>Retrospective Study of Gene Status and Clinical Outcome of Esophageal Squamous Cell Carcinoma(ESCC).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LiuJunFeng</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>OrigiMed., Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hebei Medical University Fourth Hospital</source>
  <brief_summary>
    <textblock>
      The incidence of esophageal squamous cell carcinoma is highly regional and familial. The
      current treatment plan is based on the stage and location of the tumor.By studying the
      relationship between the status of different genes and prognosis, it can help doctors to
      develop precise and individualized treatment plans.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 26, 2018</start_date>
  <completion_date type="Anticipated">April 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Gene test</measure>
    <time_frame>2019-2 to 2019-4</time_frame>
    <description>466 Tumor-associated gene test by next-generation sequencing(NGS)</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">46</enrollment>
  <condition>Prognosis of Patients With ESCC</condition>
  <arm_group>
    <arm_group_label>Lymph node metastasis Positive</arm_group_label>
    <description>good prognosis; without Lymph node metastasis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lymph node metastasis Negative</arm_group_label>
    <description>poor prognosis; with Lymph node metastasis.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Taihang Mountain area population in northern China.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Esophageal cancer patients who underwent surgery treatment, and postoperative
             pathological diagnosis was squamous cell carcinoma. Patients with ESCC have complete
             clinical information.

        Exclusion Criteria:

          -  Patients who also suffering from other tumors.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Junfeng Liu, MD</last_name>
    <phone>13931152296</phone>
    <email>13931152296@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Junfeng Liu</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Junfeng Liu, Professor</last_name>
      <phone>13931152296</phone>
      <email>13931152296@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>February 4, 2019</study_first_submitted>
  <study_first_submitted_qc>February 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 6, 2019</study_first_posted>
  <last_update_submitted>February 6, 2019</last_update_submitted>
  <last_update_submitted_qc>February 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hebei Medical University Fourth Hospital</investigator_affiliation>
    <investigator_full_name>LiuJunFeng</investigator_full_name>
    <investigator_title>Director of thoracic surgery</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

